e公司讯，普洛药业(000739)11月11日晚间公告，近日，公司控股子公司浙江普洛康裕制药有限公司收 到国家药监局签发的丁二磺酸腺苷蛋氨酸肠溶片《药品注册证书》。 丁二磺酸腺苷蛋氨酸肠溶片适用于肝硬化前和肝硬化所致肝内胆汁淤积和妊娠期肝内胆汁淤积。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2024-53 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司（以下简称"康裕制药"）收到国家药品监督管理局（以下简称 "药监局"）签发的丁二磺酸腺苷蛋氨酸肠溶片《药品注册证书》。现将有关情 况公告如下： 一、药品注册批准情况 1、产品名称：丁二磺酸腺苷蛋氨酸肠溶片 2、剂型：片剂 3、规格：0.5g 4、上市许可持有人：浙江普洛康裕制药有限公司 5、生产企业：浙江普洛康裕制药有限公司 6、证书编号：2024S02691 7、药品批准文号：国药准字 H20249303 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司一直高度重视药品研发，并非常注重药品研发、制造及销售等环节的质 量、安全和合规。但是药品的生产和销售可能会受到政策法规、市场环境变化等 不确定性因素的影响。敬请 ...

证券代码：000739 证券简称：普洛药业 公告编号：2024-52 普洛药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司（以下简称"康裕制药"）收到国家药品监督管理局（以下简称 "药监局"）下发的盐酸安非他酮缓释片（Ⅱ）《药品补充申请批准通知书》。 现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：盐酸安非他酮缓释片（Ⅱ） 2、剂型：片剂 3、规格：150mg 4、补充申请事项：新增 150mg 规格 5、上市许可持有人：浙江普洛康裕制药有限公司 6、通知书编号：2024B05020 7、药品批准文号：国药准字 H20247260 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品此次申请事项符合药品注册的有关要求，批准本品新增 150mg 规格的补充 申请事项，发给药品批准文号。 二、药品其他相关情况 盐酸安非他酮缓释片（II）用于治疗抑郁症。根据相关数据显示，盐酸安非 他酮口服剂型在国内 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [4][10] Core Views - The company has shown steady revenue growth with a significant improvement in the gross margin of its formulation segment. The revenue for the first three quarters of 2024 reached 9.29 billion yuan, an increase of 9.3% year-on-year, while the net profit attributable to the parent company was 870 million yuan, up 2.2% year-on-year [5][10] - The report highlights the strong performance of the formulation segment, while the CDMO segment experienced a decline in revenue due to a high base effect from the previous year. The raw material segment achieved revenue of 6.90 billion yuan, a year-on-year increase of 15.3%, while the CDMO segment's revenue was 1.42 billion yuan, down 11.4% year-on-year [5][9] - The company is experiencing a high growth rate in its CDMO business, with the number of quoted projects increasing by 85% year-on-year to 1,198 projects, and ongoing projects rising by 47% to 948 projects [2][9] Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a revenue of 9.29 billion yuan (+9.3%), with a net profit of 870 million yuan (+2.2%) and a non-recurring net profit of 830 million yuan (+0.4%). In Q3 alone, revenue was 2.86 billion yuan (+12.4%), while net profit was 240 million yuan (-2.2%) [5][10] - The gross margin for the formulation segment improved significantly to 62.2%, an increase of nearly 10 percentage points year-on-year, attributed to adjustments in sales models and improved production efficiency [5][9] Segment Performance - Raw Material Segment: Revenue of 6.90 billion yuan (+15.3%), gross profit of 1.08 billion yuan (-0.9%), gross margin of 15.6% (-2.6 percentage points) [5][9] - CDMO Segment: Revenue of 1.42 billion yuan (-11.4%), gross profit of 580 million yuan (-19.6%), gross margin of 40.8% (-4.2 percentage points) [5][9] - Formulation Segment: Revenue of 950 million yuan (+8.6%), gross profit of 590 million yuan (+28.0%), gross margin of 62.2% [5][9] Future Outlook - The company maintains its profit forecast, expecting net profits of 1.123 billion yuan, 1.325 billion yuan, and 1.594 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 6.4%, 18.0%, and 20.3% [10][12]

证券代码：000739 证券简称：普洛药业 公告编号：2024-51 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2024 年 10 月 29 日，普洛药业股份有限公司（以下简称"公司"）与中 国农业银行股份有限公司东阳市支行（以下简称"农业银行"）签订《保证合同》 （合同编号：33100120240015952），同意为公司控股子公司浙江普洛康裕制药 有限公司（以下简称"康裕制药"）与农业银行签署的《商业汇票银行承兑合同》 （合同编号：33180120240018143）中的 1,683.76 万元银行承兑汇票提供连带责 任保证，担保期限 6 个月。 2、2024 年 10 月 30 日，公司与中国进出口银行浙江省分行（以下简称"进 出口银行"）签订《保证合同》[合同编号：（2024）进出银（浙信保）字第 3-017 号]，同意为公司全资子公司浙江普洛家园药业有限公司（以下简称"家园药业"） 与进出口银行签署的《借款合同（出口卖方信贷）》[合同编号：（2024）进出 银（浙信合）字 ...

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 股 票 研 究 证 券 研 究 报 告 ——普洛药业 2024 年三季报点评 股票研究 /[Table_Date] 2024.10.20 [table_Authors] 丁丹(分析师) 吴晗(分析师) 0755-23976735 dingdan@gtjas.com 登记编号S0880514030001 | --- | --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | 010-83939773 | | | | | | | wuhan024878@gtjas.com | | | | | | | S0880523080005 | | | | | | 本报告导读： 业绩稳定增长，费用率改善，丰富产品管线及一体化布局保障远期业绩增长。 投资要点： [Table_Summary] 维持"增持"评级 ...

编号：2024-05 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in Q3 met expectations, with stable revenue growth during the off-peak season. The revenue for the first three quarters reached 10.54 billion yuan, a year-on-year increase of 17.92% [1] - The growth in revenue is primarily driven by the rapid expansion of the formulation segment due to centralized procurement, along with an increasing market share of core API products and a growing number of clients and projects in the CDMO business [1][2] - The company is expected to maintain robust growth in revenue and profit, with projected net profits of 1.14 billion yuan for 2023, reflecting a year-on-year growth of 7.90% [1][2] Financial Performance Summary - **Revenue (Million Yuan)**: - 2022A: 10,544.91 - 2023A: 11,474.16 (YoY growth: 8.81%) - 2024E: 12,716.23 (YoY growth: 10.82%) - 2025E: 14,004.28 (YoY growth: 10.13%) - 2026E: 15,477.21 (YoY growth: 10.52%) [1] - **Net Profit (Million Yuan)**: - 2022A: 989.17 - 2023A: 1,055.34 (YoY growth: 6.69%) - 2024E: 1,138.72 (YoY growth: 7.90%) - 2025E: 1,271.50 (YoY growth: 11.66%) - 2026E: 1,478.92 (YoY growth: 16.31%) [1] - **Earnings Per Share (Yuan)**: - 2022A: 0.84 - 2023A: 0.90 - 2024E: 0.97 - 2025E: 1.08 - 2026E: 1.25 [1] - **Market Capitalization (Million Yuan)**: - As of October 17, 2024, the market capitalization is 18,896.27 [1] Quarterly Financial Data - **Q1-Q3 2024 Revenue**: 9,290.22 million yuan, a year-on-year increase of 9.30% [2] - **Q1-Q3 2024 Net Profit**: 869.65 million yuan, a year-on-year increase of 2.15% [2] - **Operating Cash Flow**: 1,165.71 million yuan, a year-on-year increase of 37.38% [2] Future Outlook - The company is expected to continue its growth trajectory, with revenue projected to reach 12.72 billion yuan in 2024 and net profit expected to grow to 1.14 billion yuan [1][2] - The company maintains a strong competitive position in the industry, supported by its diversified business strategy and continuous improvement in operational efficiency [1][2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 9.29 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 9.30%, with a net profit attributable to shareholders of 870 million yuan, up 2.15% [2] - In Q3 alone, the company achieved a revenue of 2.862 billion yuan, an increase of 12.41%, while the net profit attributable to shareholders was 245 million yuan, down 2.19% [2] - The significant decrease in sales expense ratio is attributed to enhanced cost control and optimized market strategies, while the increase in financial expenses is mainly due to exchange losses [2] - The company is progressing well in integrated development, with over 25 formulation projects initiated annually, and is expected to see growth in related products by 2025 [2] - The profit forecast for 2024-2026 has been adjusted to 11.9 billion, 13.8 billion, and 15.6 billion yuan respectively, with a current market value corresponding to P/E valuations of 16, 14, and 12 times [2] Summary by Sections Financial Performance - Total revenue for 2022 was 10.545 billion yuan, with a year-on-year growth of 17.92%, and for 2023, it was 11.474 billion yuan, with a growth of 8.81% [1] - The net profit attributable to shareholders for 2022 was 989.17 million yuan, with a growth of 3.52%, and for 2023, it was 1,055.34 million yuan, with a growth of 6.69% [1] - The latest diluted EPS for 2024 is projected to be 1.02 yuan per share, with a P/E ratio of 15.69 [1] Cost Management - The sales expense ratio for Q3 was 4.16%, down 2.2 percentage points, while the management expense ratio was 4.54%, up 0.06 percentage points [2] - The R&D expense ratio was 5.31%, up 0.13 percentage points, and the financial expense ratio was 1.12%, up 1.86 percentage points due to exchange losses [2] Strategic Development - The company is enhancing its technical platforms and has signed a strategic cooperation framework agreement to strengthen its capabilities in synthetic biology and enzyme catalysis [2] - The integrated development strategy is expected to support the growth of the company's various business segments [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][11]. Core Views - The company achieved steady revenue growth in the first three quarters of 2024, with revenue reaching 9.29 billion yuan (up 9.3% year-on-year) and net profit attributable to shareholders of 870 million yuan (up 2.15% year-on-year) [3]. - The company has signed a strategic cooperation agreement with Baikuirui to enhance its research and production capabilities in protein and peptide drugs [5]. Financial Performance Summary - For the first three quarters of 2024, the company reported: - Revenue: 9.29 billion yuan (up 9.3%) - Net profit: 870 million yuan (up 2.15%) - Non-recurring net profit: 831 million yuan (up 0.4%) - Gross margin: 24.23% (down 2.55 percentage points) - Net margin: 9.36% (down 0.66 percentage points) [3]. - In Q3 2024, the company recorded: - Revenue: 2.862 billion yuan (up 12.41%) - Net profit: 245 million yuan (down 2.19%) - Non-recurring net profit: 229 million yuan (down 1.75%) - Gross margin: 23.18% (down 4.02 percentage points) - Net margin: 8.55% (down 1.28 percentage points) [3]. - The company maintains its profit forecast, expecting net profits of 1.238 billion yuan, 1.462 billion yuan, and 1.700 billion yuan for 2024, 2025, and 2026 respectively, with current price-to-earnings ratios of 15.3, 12.9, and 11.1 times [3]. Financial Ratios and Projections - Key financial metrics for 2024E: - Revenue: 13.029 billion yuan (up 13.6%) - Net profit: 1.238 billion yuan (up 17.3%) - Gross margin: 26.0% - Net margin: 9.5% - Return on equity (ROE): 17.5% - Earnings per share (EPS): 1.06 yuan [6]. - The company’s financial expenses increased by 74 million yuan year-on-year due to exchange losses, compared to exchange gains in the same period last year [4].